Updated and contextualized version of an article originally published on July 13, 2014
The article retains its original focus by presenting it through a scholarly and accessible perspective, supported by verifiable references.
Authors
- Dr. A. Colonnese – Nutrition biologist
- Roberto Panzironi –Independent researcher
Note editoriali
- First publication: July 13, 2014
- Last update: April 20, 2026
- Version: 2026 narrative revision
In brief
- Evidence from randomized clinical trials indicates that vitamin D supplementation does not consistently reduce the total incidence of cancers, but some meta-analyses and secondary analyses suggest a possible reduction in cancer mortality or advanced cases in specific contexts.
- Large prevention trials (e.g., VITAL) have yielded neutral results for total cancer incidence and cardiovascular diseases, but some subgroups and secondary analyses show signals of possible benefit for advanced outcomes or mortality. [1][2][3]
- Observational associations between low serum 25(OH)D levels and increased risk of certain diseases exist, but are not proof of causality: clinical trials remain necessary to establish causal effects. [4][7]
- For other conditions (type 1 and 2 diabetes, cardiovascular diseases) the evidence is mixed: some signals in observational studies, but negative or neutral results in the largest randomized trials. [5][6][7]
Abstract: what does science say?
Vitamin D is a fat-soluble hormone produced in the skin after sun exposure and found in some foods and supplements. Observational studies have linked higher levels of 25-hydroxyvitamin D (25(OH)D) to a lower risk or improved survival for various cancers; however, experimental evidence is more complex. Meta-analyses of randomized studies show a modest effect on cancer mortality in several cases, but no clear reduction in overall incidence. Large, recent trials (e.g., VITAL) have not demonstrated significant reductions in cancer incidence or cardiovascular events overall, although they offer secondary signals on advanced cancer reduction in some subgroups. Biological plausibility exists (immune modulation, cell differentiation), but evidence of causality remains incomplete: results depend on dose, duration, nutritional status, and characteristics of the studied population.
Vitamin D and cancer: main evidence
The literature on vitamin D and cancer is divided into three main blocks: observational studies (cohorts and case-controls), meta-analyses of randomized studies, and individual clinical trials. Updated meta-analyses of randomized trials show that supplementation with moderate dosages may not reduce the total incidence of tumors, but some works report a reduction in overall cancer mortality. [1][4] This pattern—stronger associations with mortality than with incidence—is consistent with biological hypotheses that vitamin D may influence progression or prognosis more than the initial onset of cancer.
The large randomized VITAL trial (2,000 IU/day) did not show a significant reduction in the incidence of invasive cancers compared to placebo, but a secondary analysis reported a reduction in metastatic or fatal cancer events, especially in individuals with normal BMI. [2][3] This suggests that the effect may vary by subgroup and depend on metabolic or pharmacokinetic conditions.
Other trials and studies on specific tumor sites (e.g., colorectal) have shown favorable signals in survival or progression in therapeutic contexts (e.g., high-dose supplementation in patients with advanced colorectal cancer), but the results are heterogeneous and often of limited size. [8][9]
Biological mechanisms and plausibility
Biologically, vitamin D and its metabolites modulate gene transcription through the vitamin D receptor (VDR), influencing cell proliferation, differentiation, apoptosis, and immune responses. These mechanisms make a role in modulating tumor growth and the micro-tumor environment plausible. However, the translation of cellular mechanisms into population-level clinical benefits requires experimental confirmation in appropriate clinical studies.
Furthermore, pharmacokinetic factors (body mass index, fat reserves, sun exposure, dietary intake) and administration methods (daily dose vs. bolus) influence circulating levels of 25(OH)D and may explain differences between studies. For example, some meta-analyses suggest that constant daily doses may have different outcomes compared to intermittent high-dose administrations. [1][7]
What this means in practice
For the general public: maintaining adequate vitamin D levels is reasonable for bone and general health, but there is no definitive evidence that universal supplementation prevents all cancers. Clinical guidelines recommend targeted interventions (screening and supplementation) for groups at risk of vitamin D deficiency (e.g., the elderly, people with limited sun exposure, malabsorption, very pigmented skin), avoiding excessive doses without medical supervision.
In patients with a cancer diagnosis, some small or secondary clinical studies suggest a possible benefit of vitamin D on prognosis in specific situations (e.g., metastatic colorectal cancer), but the evidence is not yet robust enough to recommend high-dose supplementation as cancer therapy. Personalized discussions with an oncologist and measurement of 25(OH)D are advisable before undertaking high dosages. [8][9]
Key points to remember
- An observational association between low 25(OH)D levels and the risk or worse prognosis of certain cancers exists, but does not prove direct causality.
- Large-scale randomized trials have not shown a clear reduction in the total incidence of cancer; some meta-analyses and secondary analyses report a reduction in mortality or advanced stages in certain contexts. [1][2][3]
- The effects seem to depend on dose, duration, nutritional status, and population characteristics (e.g., BMI), and differ between daily dosages and boluses. [1][7]
- For primary prevention of oncological disease, the evidence is incomplete; for individual health, it is appropriate to correct documented deficiencies with clinical mediation.
Limitations of Evidence
It is important to distinguish between observational studies and causal evidence provided by randomized trials. Observational studies can be confounded (physical activity, nutritional status, sun exposure, comorbidities) and subject to reverse causation bias (the disease influences 25(OH)D levels). Randomized trials offer greater causal strength, but often were not primarily designed for oncological endpoints and have variable durations and dosages.
Frequent methodological limitations include: heterogeneity in vitamin D dosages and forms (D2 vs D3), use of off-protocol supplements in placebo groups, relatively short follow-up for oncological outcomes, and insufficient statistical power for tumor subtypes. These limitations require cautious interpretation of results and further targeted studies. [1][4][7]
Editorial Conclusion
Research on vitamin D and cancer shows interesting but not definitive results. Evidence suggests that vitamin D may influence tumor prognosis and mortality in some contexts, but there is no robust proof that supplementation generally reduces the incidence of all cancers in the healthy population. Clinical decisions regarding testing and supplementation should be personalized, based on 25(OH)D measurements, individual risk factors, and dialogue with the treating physician. Further well-designed trials are needed, with adequate dosages and durations, and with attention to subgroups that might benefit most.
Editorial Note
This update integrates results from recent clinical studies and meta-analyses to offer a critical and accurate reading of the evidence. The aim is to inform with balance: no specific therapeutic indications are provided. For personal or therapeutic choices, consult a healthcare professional. Original source of the content originally published: Dr. Francesco Perugini Billi. The text also cites the contribution of international experts and research; complete references are provided in the Scientific Research section.
Scientific research
- Keum N, et al. Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019. https://doi.org/10.1093/annonc/mdz059 [Verified].
- Manson JE, et al.; VITAL Research Group. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease. N Engl J Med. 2019;380:33–44. https://doi.org/10.1056/NEJMoa1809944 [Verified].
- Chandler PD, et al. Effect of Vitamin D3 Supplements on Development of Advanced Cancer: A Secondary Analysis of the VITAL Randomized Clinical Trial. JAMA Netw Open. 2020. https://doi.org/10.1001/jamanetworkopen.2020.32460 [Verified].
- Keum N, Giovannucci E. Vitamin D supplements and cancer incidence and mortality: a meta-analysis. Br J Cancer. 2014;111:976–980. https://doi.org/10.1038/bjc.2014.294 [Verified].
- Pittas AG, et al.; D2d Research Group. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019;381:520–530. https://doi.org/10.1056/NEJMoa1900906 [Verified].
- Hyppönen E, et al. Intake of vitamin D and risk of type 1 diabetes: a birth‑cohort study. Lancet. 2001;358:1500–1503. https://doi.org/10.1016/S0140-6736(01)06580-1 [Verified].
- Mao S, et al. Vitamin D supplementation and cardiovascular disease risks in randomized clinical trials: meta-analysis (JAMA Cardiol 2019). https://doi.org/10.1001/jamacardio.2019.1870 [Verified].
- Vaughan‑Shaw PG, et al. The effect of vitamin D supplementation on survival in patients with colorectal cancer: systematic review and meta-analysis of randomised controlled trials. Br J Cancer. 2020;123:1705–1712. https://doi.org/10.1038/s41416-020-01060-8 [Verified].
- Ng K, et al. Effect of High‑Dose vs Standard‑Dose Vitamin D3 Supplementation on Progression‑Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer (SUNSHINE trial). JAMA. 2019;321(14):1370–1379. https://doi.org/10.1001/jama.2019.2402 [Verified].